Loading...

Apellis Pharmaceuticals, Inc.

APLS•NASDAQ
Healthcare
Biotechnology
$40.94
$0.04(0.10%)
U.S. Market opens in 3h 7m

Apellis Pharmaceuticals, Inc. (APLS) Stock Overview

Explore Apellis Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap5.2B
P/E Ratio230.31
EPS (TTM)$0.18
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$19.52
3 Months$10.65
1 Year Target$4.33

APLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Apellis Pharmaceuticals, Inc. (APLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 88.15, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $4.33.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 230.31 and a market capitalization of 5.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.10%
5-Day Change
0.22%
1-Month Change
137.88%
3-Month Change
100.00%
6-Month Change
51.24%
Year-to-Date (YTD) Change
62.98%
1-Year Change
127.07%
3-Year Change
-50.33%
5-Year Change
-10.98%
All-Time (Max) Change
191.80%

Contact Information

https://www.apellis.com
617 977 5700
100 Fifth Avenue, Waltham, MA, 02451

Company Facts

705 Employees
IPO DateNov 9, 2017
CountryUS
Actively Trading

Frequently Asked Questions